October 8, 2025
Werewolf Therapeutics Receives Fast Track Designation from the U.S. FDA for WTX-124, an Investigational Therapy for the Treatment of Cancer
WATERTOWN, Mass., October 8, 2025 — Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”)